AbbVie Bets Big on Respiratory Pipeline with Apogee Acquisition -- Company Talk
Dow Jones
Jun 22
AbbVie's $10.9 billion cash acquisition of Apogee Therapeutics marks an expansion beyond dermatology into the respiratory space. The deal brings a pipeline targeting atopic dermatitis and asthma, areas where AbbVie sees unmet patient needs. Chairman and CEO Robert A. Michael said the acquisition strengthens the company's ability to deliver innovative medicines while creating long-term shareholder value. AbbVie has led the immunology field for more than two decades, and this deal adds clinical-stage assets that complement its existing portfolio rather than replace it
This article was automatically created using artificial-intelligence technology and reviewed by Dow Jones Newswires editors.
(END) Dow Jones Newswires
June 22, 2026 07:45 ET (11:45 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.